metastatic castration-resistant prostate cancer
FDA Expands Pluvicto’s Metastatic Castration-Resistant Prostate Cancer Indication
The FDA expanded the indication for(Pluvicto to include adults with PSMA-positive metastatic castration-resistant ...
APRIL 2, 2025
New Indication Granted for Lynparza for BRCA-mutated mCRPC
The FDA granted a new indication for Lynparza with abiraterone and a steroid for adult patients with deleterious or ...
JUNE 2, 2023
Load more